FDA Approves New Use for Rifaximin

The FDA has approved rifaximin (Xifaxan) to reduce the risk for recurrence of overt hepatic encephalopathy in patients with advanced liver disease.

Rifaximin, previously approved to treat traveler's diarrhea, reduces blood levels of ammonia, which are thought to influence the development of hepatic encephalopathy.